unknown
Stage
1
Investors
About
Helicore Biopharma develops long-acting antibody-peptide conjugate therapies targeting obesity and cardiometabolic diseases using proprietary engineered peptides and a GIP ligand-binding antibody platform.
Explore Helicore Biopharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.